Ignite Creation Date:
2024-05-05 @ 10:23 AM
Last Modification Date:
2024-10-26 @ 9:03 AM
Study NCT ID:
NCT00003538
Status:
COMPLETED
Last Update Posted:
2014-05-02
First Post:
1999-11-01
Brief Title:
Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Organization:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study Overview
Official Title:
Stem Cell Augmented Elutriated Grafts for Allogeneic Bone Marrow Transplantation
Status:
COMPLETED
Status Verified Date:
2014-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells Sometimes the transplanted cells can make an immune response against the bodys normal tissues Stem cells that have been treated in the laboratory to remove lymphocytes may prevent this from happening
PURPOSE Clinical trial to prevent graft-versus-host disease in patients undergoing bone marrow transplantation
PURPOSE Clinical trial to prevent graft-versus-host disease in patients undergoing bone marrow transplantation
Detailed Description:
OBJECTIVES
Determine whether stem cell augmented elutriated grafts prevent graft versus host disease in patients undergoing allogeneic bone marrow transplantation
OUTLINE Patients receive elutriated CD34 augmented donor bone marrow on day 0
Bone marrow samples are obtained before day 100 around 6 months and 1 year after transplant
PROJECTED ACCRUAL Not specified
Determine whether stem cell augmented elutriated grafts prevent graft versus host disease in patients undergoing allogeneic bone marrow transplantation
OUTLINE Patients receive elutriated CD34 augmented donor bone marrow on day 0
Bone marrow samples are obtained before day 100 around 6 months and 1 year after transplant
PROJECTED ACCRUAL Not specified
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| NCI-V98-1460 | US NIH GrantContract | None | httpsreporternihgovquickSearchP30CA006973 |
| P30CA006973 | NIH | None | None |
| JHOC-97021903 | None | None | None |
| JHOC-J9711 | None | None | None |